Sharemaestro Newsreel

Adlai Nortye (Nasdaq: ANL) shifts to Singapore with super-voting shares

Adlai Nortye Group Ltd. (ANL) has completed a corporate reorganization, redomiciling from the Cayman Islands to Singapore and changing its name to "Adlai Nortye Group Ltd." The company also adopted a new Singapore-law constitution establishing a dual-class share structure where Class A Ordinary Shares …

CareCloud confirms 3.7M patients had their medical records stolen in data breach

CareCloud, a health data giant, has confirmed that hackers stole personal information and medical records of over 3.75 million people in a data breach. This incident marks the fifth-largest theft of health data in 2026 so far. The stolen data includes names, addresses, Social …

Form 8K Aspire Biopharma Holdings Inc For: 19 August By Investing.com

This article reports on Aspire Biopharma Holdings Inc.'s Form 8K filing for August 19. The filing is a standard SEC disclosure for material events that shareholders should know about. The company's stock symbol is ASBP, and it showed a 5.24% increase.

HC Wainwright Lowers Earnings Estimates for Kodiak Sciences

HC Wainwright has revised its Q3 2026 earnings per share (EPS) estimates for Kodiak Sciences, lowering it to a loss of $0.89 from $0.80, while maintaining a "Buy" rating and a $58 price target. This adjustment follows Kodiak Sciences reporting a Q2 loss of …

ETFs Investing in ICON Plc Stocks

This article lists various ETFs that hold ICON Plc stocks, providing a table with details such as market value, weight, issuer, management style, focus, expense ratio, AUM, price, change, relative volume, and 3-year NAV total return for each fund. The purpose is to offer …

Oncolytics Biotech (NASDAQ:ONCY) Price Target Cut to $5.00 by Analysts at HC Wainwright

HC Wainwright has reduced its price target for Oncolytics Biotech (NASDAQ:ONCY) to $5.00, while maintaining a "Buy" rating, implying a significant potential upside. The company reported a quarterly loss of $0.08 per share, missing estimates. Analyst sentiment is mixed, with a consensus "Moderate Buy" …

Form 8K MediciNova Inc For: 19 August By Investing.com

This article announces the filing of a Form 8K by MediciNova Inc. on August 19. It provides basic information about the filing and mentions the stock symbol MNOV along with its current performance. The content is primarily a brief news alert from Investing.com.

EXELIXIS INC : BMO INITIATES COVERAGE WITH MARKET PERFORM RATING; PRICE TARGET $54

BMO has initiated coverage on Exelixis Inc. (EXEL.O) with a "Market Perform" rating. The firm has set a price target of $54 for the biotechnology company. This information was reported by Reuters.

DocGo Raises SteadyMD Earnout Liability To $5 Million From $2.3 Million As Telehealth Revenue Outlook Improves

DocGo has increased its estimated contingent consideration liability for the SteadyMD acquisition from $2.3 million to $5 million, reflecting a more optimistic revenue outlook for the telehealth business. This adjustment resulted in a $2.7 million fair-value loss in the first half but indicates an …

Mereo BioPharma Group's (MREO) "Underweight" Rating Reiterated at JPMorgan Chase & Co.

JPMorgan Chase & Co. has reiterated its "underweight" rating for Mereo BioPharma Group (MREO), despite "buy" ratings from other firms like Needham and BTIG. The stock holds an overall "Hold" rating from analysts with an average price target of $3.25. Mereo BioPharma Group reported …

Intelligent Bio Solutions grows to 502 customers as net loss widens to $12.5M

Intelligent Bio Solutions (INBS) reported a 38% year-over-year revenue increase to $4.2 million for fiscal 2026, driven by a 22% expansion in its reader installed base and a 35% rise in consumable cartridge sales. Despite improved gross profit margins, the company's net loss widened …

Intelligent Bio Solutions Reports Fiscal 2026 Revenue Up 38% to $4.22M, Gross Margin 48.63%

Intelligent Bio Solutions (INBS) announced a 38% increase in fiscal 2026 revenue, reaching $4.22 million, with gross profit rising by 64% and gross margin expanding to 48.63%. Despite a net loss of $(12.43) million, the company reported significant progress in FDA 510(k) submission, a …

INTELLIGENT BIO SOLUTIONS INC. FY 2026: Revenue $4.22M, EPS $(8.44) — 10-K Summary

Intelligent Bio Solutions Inc. reported its fiscal year 2026 results, showing revenue of $4.22 million, a 38.1% increase year-over-year, and a net loss of $12.43 million with an EPS of $(8.44). The company highlighted growth drivers including increased demand for consumable cartridges, new customers, …

Novo Nordisk Starts Testing Lower-Doses of Its Wegovy Weight-Loss Pills

Novo Nordisk is testing lower doses of its Wegovy weight-loss pill to determine the minimum effective level for patients. The study, which began recently and involves 450 overweight individuals, will compare two undisclosed low doses against a placebo. This research aims to find more …

Q1 EPS Forecast for UnitedHealth Group Lifted by Analyst

Zacks Research has increased its Q1 2027 EPS forecast for UnitedHealth Group (NYSE:UNH) to $7.12, maintaining a "Strong Buy" rating. The healthcare conglomerate recently reported Q1 earnings of $6.38 per share, surpassing the consensus estimate, and revenue of $112.03 billion, also exceeding expectations. Analyst …

BTAI: At Home Agitation Data And Index Additions Will Drive Upside

BioXcel Therapeutics (BTAI) has seen its fair value estimate increase significantly, driven by updated assumptions in revenue growth, profit margins, and future P/E levels. The company also announced positive Phase 3 trial data for BXCL501 and was added to several Russell Growth and Microcap …

Amneal (AMRX) Earnings Report: EPS Beats Its Estimate in Latest Trading; The Market Price Declines 1.25% in the Latest Session - Diluted EPS Report

Baxter International Names John Rogers Chief Financial Officer

Baxter International has appointed John Rogers as its new Chief Financial Officer. This announcement follows closely after several other recent developments for the company, including pricing its upsized cash tender offers and amending its five-year credit agreement. The company has also seen recent analyst …

Baxter appoints John Rogers as CFO; Andrew Hider interim CFO

Baxter has announced the appointment of John Rogers as Executive Vice President and Chief Financial Officer, effective October 1, 2026. Andrew Hider will serve as interim CFO from September 15, 2026, until Rogers takes over, with Bernie Heine appointed as interim Chief Accounting Officer …

Q3 EPS Estimates for Alpha Cognition Decreased by Analyst

Align (ALGN) Quarterly Results: The Available Earnings Metric Delivers a Miss in the Available Record; Post-Report: Shares Fall 1.90% on the Day - Earnings Weakness Phase

H.C. Wainwright reiterates Microbot Medical stock rating on revenue growth

H.C. Wainwright has reiterated a Buy rating and a $12.00 price target for Microbot Medical (NASDAQ:MBOT) following strong second-quarter 2026 financial results, which saw revenue exceed analyst projections and grow over 100% quarter-over-quarter. Despite a net loss, the company's LIBERTY System has seen increased …

Option (OPCH) Results Review: EPS Lands Above Forecast in the Latest Session; The Market Price Advances 0.17% on the Day - Return On Assets

VRAX Stock Whipsaws As Traders Target Volatile Biotech Play

Revolution Medicines (RVMD) Is Up 5.1% After Offloading Phase 3 Costs to BeOne Medicines

Revolution Medicines (RVMD) saw a 5.1% stock increase after partnering with BeOne Medicines. This collaboration shifts the financial burden of a global Phase 3 study for one of Revolution's RAS(ON) inhibitors to BeOne, while also granting BeOne regional commercialization rights in certain Asian markets. …

Amphastar (AMPH) Quarterly Results: EPS Exceeds Its Estimate in Latest Trading; Trading Response: The Stock Ends Up 2.30% on the Day - Earnings Weakness Phase

Hematogenix's MM MRD Assay Underpins FDA Accelerated Approval of Bristol Myers Squibb's ZENBEXUS™, the First Approved CELMoD Therapy for Multiple Myeloma

Hematogenix's proprietary Multiple Myeloma MRD (MM MRD) assay measured the primary efficacy endpoint cited in the FDA-approval of ZENBEXUS (iberdomide), reinforcing Hematogenix's role as a specialized global leader in registrational oncology trials.Hematogenix Log TINLEY PARK, Ill., Aug. 19, 2026 Hematogenix®, a global specialty laboratory …

TG Therapeutics (NASDAQ:TGTX) Combines Strong Growth with a Breakout Setup

Intelligent Bio (NASDAQ: INBS) warns on cash and survival

Acrivon (ACRV) Results Breakdown: EPS Exceeds Its Estimate in the Latest Session; Post-Report: The Stock Closes Near Unchanged on the Day - Full Year Guidance

Auna S.A. 2026 Q2 - Results - Earnings Call Presentation (NYSE:AUNA) 2026-08-19

Tenet Healthcare (THC) Stock Still Looks Like A Bargain On A 272% Run

Evogene Ltd. Q2 2026 Earnings Call Summary

HC Wainwright Issues Pessimistic Forecast for AVBP Earnings

Research Analysts Issue Forecasts for ALDX Q3 Earnings

DaVita stock slips after Q2 revenue beats forecasts

DaVita Inc. (US23918K1088) reported strong Q2 2026 results, with revenue of $3.55 billion and adjusted EPS of $4.02, exceeding analyst expectations. Despite these positive financial figures and a 5.2% year-over-year revenue increase, the stock experienced a 1.87% decline. Analysts maintain a "Hold" rating with …